Daxor (DXR) Insider Ownership : 65.25 % (As of Apr. 27, 2024)

View and export this data going back to 1992. Start your Free Trial

What is Daxor Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Daxor's insider ownership is 65.25%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Daxor's Institutional Ownership is 2.13%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Daxor's Float Percentage Of Total Shares Outstanding is 42.66%.

Daxor Insider Ownership Historical Data

The historical data trend for Daxor's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daxor Insider Ownership Chart

Daxor Historical Data

The historical data trend for Daxor can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Insider Ownership	65.29	65.29	65.29	65.29	65.34	65.40	65.40	65.40	65.40	65.25

Daxor Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Daxor (DXR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

DX5:Germany

Address

109 Meco Lane, Oak Ridge, TN, USA, 37830

Website

https://www.daxor.com

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Executives

Robert J Michel	officer: CHIEF FINANCIAL OFFICER	C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh	director	71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers	director	DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer	director	2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson	officer: V.P./BUSINESS DEVELOPMENT	180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh	director, officer: CHIEF SCIENTIFIC OFFICER	DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh	officer: President	615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh	other: FOUNDER	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan	officer: Corporate Secretary	259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe	director	6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens	director	200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson	director	P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom	officer: Vice President	3244 BLACK FOX ROAD, WASHBURN TN 37888